title: Carotid stenosis: from diagnosis to management, where do we stand?
abstract: Carotid atherosclerosis is implicated in 20-30 % of strokes. However, the annual risk of stroke in patients with asymptomatic carotid stenosis is less than 5 %. Symptomatic carotid stenosis poses a greater risk for recurrent stroke with estimates as high as 15 % per year. This paper aims to raise awareness of populations at risk for carotid stenosis, the role of carotid screening and the sensitivity and specificity of various diagnostic modalities. The results of previous trials that support current guidelines for management of symptomatic and asymptomatic carotid stenosis will also be reviewed.
authors.affiliation: Westchester Medical Center, New York Medical College, 100 Woods Rd, Valhalla, NY, 10595, USA, rgokaldas@gmail.com.
authors.forename: Reshma
authors.initials: R
authors.lastname: Gokaldas
authors.forename: Maheep
authors.initials: M
authors.lastname: Singh
authors.forename: Sonia
authors.initials: S
authors.lastname: Lal
authors.forename: Ricardo J
authors.initials: RJ
authors.lastname: Benenstein
authors.forename: Ramandeep
authors.initials: R
authors.lastname: Sahni
mesh_terms: D000800:Angioplasty, Balloon; D002340:Carotid Artery Diseases / Q000150:complications / Q000628:therapy; D016893:Carotid Stenosis / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D016894:Endarterectomy, Carotid; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008403:Mass Screening; D018570:Risk Assessment; D015607:Stents; D020521:Stroke / Q000209:etiology / Q000517:prevention & control
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors